Evaluation of the Effectiveness of Femoral Neck Prophylactic Surgery in Elderly Osteoporotic Patiens to Prevent Hip Fractures by Chiarello, Eugenio
	 1	
Alma Mater Studiorum – Università di Bologna 
 	
DOTTORATO DI RICERCA IN 	
SCIENZE BIOMEDICHE 
 
Ciclo XXVIII 
 
Settore Concorsuale di afferenza: 06/F4 
 
Settore Scientifico disciplinare: MED/33 
 
 
TITOLO TESI 	
EVALUATION OF THE EFFECTIVENESS OF 
FEMORAL NECK PROPHYLACTIC SURGERY IN 
ELDERLY OSTEOPOROTIC PATIENTS TO 
PREVENT HIP FRACTURES 
 
 
 
Presentata da: Dott. Eugenio Chiarello  
 
 
 
 
Coordinatore Dottorato     Relatore 
 
Prof. Lucio Ildebrando                           Prof. Roberto Emanuele  
                Cocco                                                        Buda               
 
  
 
 
 
 
 
Esame finale anno 2016 
 
	 2	
 
 
CONTENTS 
 
 
 
 
 
1. INTRODUCTION                 3  
 
2. MATERIALS AND METHODS     10  
 
3. RESULTS         14  
 
4. DISCUSSION         18  
 
5. CONCLUSIONS        20  
 
6. FIGURES AND TABLES     21 
 
7. REFERENCES        28 
 
 
 
 
 
 
	 3	
1. INTRODUCTION 
 
Osteoporosis is a skeletal disorder characterized by an increased risk 
of fractures due to a compromised bone strength [1, 2]. The strength 
reflects both density and quality of bone, therefore the decrease of 
bone mass and the micro-architectural deterioration that occur in this 
disease cause bone frailty leading to low energy fracture [3-5]. 
Fragility fractures are one of the major causes of morbidity and 
mortality worldwide. In Italy, there are 80.000 new femoral neck 
fractures due to osteoporosis every year, with a high prevalence in 
women (72%) [6]. Moreover, was estimated that in 2012 the cost of 
femoral fractures was 1.1 billion euro [7]. 
Osteoporosis prevalence is likely to rise due to an aging population: 
people older than 60 will increase by 50% over the next 40 years. 
Although numbers are uncertain, the latest pessimistic estimates lead 
us to expect a doubling of fragility fractures by 2050 [8, 9]. 
Moreover, hip fractures are associated with an increased mortality up 
to 25-30% within the first year [10] and an increase of 2.5 times risk of 
a new fracture [11]. One year after a hip fracture 40% of patients are 
still unable to walk independently, 60% have difficulty in at least one 
of the normal daily living activities and 80% experience limitations in 
other activities such as driving and shopping. In addition, 27% of 
patients were hospitalized in a long-term care facility following a hip 
fracture [12]. 
This scenario shows how osteoporosis and femoral neck fractures 
represent a tremendous concern in economic and social terms, 
therefore new strategies must be sought for the prevention and 
treatment of this pathology. 
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1.1 PREVENTION OF THE SECOND CONTRALATERAL FEMORAL 
NECK FRACTURE 
In literature the incidence of second contralateral hip fractures in 
elderly osteoporotic patients ranges from 7 to 12% within two years 
after the first femoral neck fracture, with a high percentage of 
symmetry between the two fractures which varies from 70% to 83% 
[13, 14]. 
Therefore, it is mandatory to adopt appropriate strategies to prevent 
the second fracture in these patients. Currently secondary prevention 
focuses on pharmacological and non-pharmacological therapy. 
The pharmacological secondary prevention is based on the 
prescription of anti-osteoporotic drugs. 
In the market, there are several classes of drugs with different 
mechanism of action: anti-absorbable, anabolic, hormone 
replacement and selective estrogen receptor modulators and 
monoclonal antibodies. 
Bisphosphonates are a class of anti-absorbable drugs with high 
tropism for the mineralized tissues. They are able to concentrate 
electively on remodeling bone surfaces, blocking osteoclast activity 
[15-18]. 
Teriparatide (rh-PTH) is an anabolic drug that stimulates bone 
formation and increases bone mineral density [19, 20]. 
Hormone replacement therapy, as the name suggests, is based on 
the substitution of estrogens whose production decreases in 
menopausal women; however, this class of drugs is associated with a 
high risk of uterine and breast cancer and increased cardiovascular 
risks [21-23]. In order to overcome these complications, selective 
estrogen receptor modulators (SERMs) such as Raloxifene and 
Bazedoxifene were introduced. These drugs explicate their action on 
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the estrogen receptors on the bone cells without having the negative 
effects on breast and uterus [24-26]. 
The last class of drug introduced in the marked are the monoclonal 
antibodies. Currently only Denosumab is available; this is an IgG2 
human monoclonal antibody directed against RANK-L, which binds 
with high affinity and specificity. These bindings prevent the activation 
of its receptor RANK present on osteoclasts and their precursors’ 
surface thereby inhibiting their formation, functionality and survival 
and thus reducing both cortical and trabecular bone resorption. [27, 
28]. 
Although there are so many drugs for the treatment and prevention of 
osteoporosis, it has been showed that none of these attain significant 
efficacy for the prevention of hip fractures below three years of 
continuous treatment [29, 30]. This combined with poor patient 
compliance results in a lack of efficacy of drugs for the secondary 
prevention of femoral neck fractures [31]. Recently some authors 
argue that evidence for drug therapy to prevent hip fracture is 
insufficient to warrant the current approach. They believe that 
pharmacotherapy can achieve at best a marginal reduction in hip 
fractures at the cost of unnecessary psychological harms, serious 
medical adverse events, and forgone opportunities to have greater 
impacts on the health of older people. Therefore, they propose to 
regret the current approach to hip fracture prevention because it is 
neither viable as a public health strategy nor cost effective [32]. 
The non-pharmacological prevention is based on modification of 
environmental risk factors, on a healthy diet with daily supplements of 
calcium and vitamin D and on the use of hip protectors. A Cochrane 
review on the use of hip protectors has demonstrated that their 
effectiveness in reducing fractures in nursing home patients but 
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equally it has shown that they are less effective in patients living in 
community. These results are probably related to the adherence of 
patients in wearing hip protectors due to their discomfort [33]. 
Currently, in addition to pharmacological and non-pharmacological 
prevention we need to add a new type of prevention: the surgical one. 
 
1.2 SURGICAL PREVENTION OF FEMORAL NECK FRACTURE 
The cortical thinning and the trabecular bone loss are both important 
in the frail osteoporotic bone. The cortical thinning of long bones is 
the consequence of endosteal resorption and normally is 
compensated by periosteal bone apposition, leading to an increase in 
the diameter of the bone. The femoral neck is not covered by 
periosteum because it is intracapsular, and therefore there isn’t bone 
apposition [3]; this may partially explain why, in osteoporotic femur, 
the neck is the "locus minoris resistentiae".  
Moreover Holzer et al. show in an in vitro study that in the femoral 
neck the cortical bone and its geometry are primarily responsible for 
the bone strength, whereas the trabecular bone gives a marginal 
contribution (less than 10%) due to morphological changes [34]. 
The rationale of surgical reinforcement is the need to increase the 
resistance of the neck to the compression and distraction forces 
acting on it [34, 35].  
During gait, the major stresses occur in the subcapital and middle-
cervical regions: high compressive stress occurs inferiorly and mild 
distraction stress occurs superiorly [36]. During a fall to the side with 
impact on the greater trochanter, the stresses are reversed: on the 
superior side of the femoral neck, a huge compressive stress occurs 
while on the inferior side there is a distraction stress [36, 37].  
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The concept of surgical reinforcement of the femoral neck was 
proposed for the first time in 1960 by Crockett [38] who described a 
reinforcement technique of the femoral neck characterized by 
percutaneous insertion of stainless-steel nails under local anesthesia. 
In the conclusion of his paper the author affirmed that in case of a 
fracture in the reinforced neck, the patient would have a non-
displaced fracture and therefore the treatment required was only rest 
and walking with 2 crutches. 
More recently, Heini et al. [39] in 2004 described another 
experimental technique called “femoroplasty” consisting of injection of 
poly-methyl-methacrylate (PMMA) inside osteoporotic femoral neck. 
The author used 20 pairs of osteoporotic femurs, each pair as a case-
control, to assess the surgical reinforcement. The author inserted a 
low viscosity cement in a 4.5 mm hole on the lateral cortex at the 
base of the greater trochanter. Subsequently the femurs were tested 
by simulating a fall. Fracture type observed in control group matched 
those commonly seen in vivo; in the study group, different fracture 
patterns were observed: trochanteric and medial fractures of the 
femoral neck and in three cases subtrochanteric fractures. Moreover, 
all the fractures occurred at the bone-cement interface. In this study 
group femurs had an increased breaking load greater than 82% 
compared to controls, and an increase in absorbed energy of 188%. 
However the author concluded that there is concerns in the 
application of this technique in vivo due to the high volume of PMMA 
necessary which generates enormous heat during polymerization (up 
to 60° in vivo) leading to necrosis of the femoral head. Moreover, 
revision surgery in event of fracture would be technically very difficult.  
Other authors [40] tested ten pairs of osteoporotic human femurs, 
each pair as a case-control, augmented with about 40 ml of another 
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low viscosity cement. They simulated a fall on the greater trochanter 
and confirmed the increase of breaking load and absorbed energy in 
the augmented femurs; however it was unknown if this increase 
would be enough to prevent fracture in vivo. Moreover, they found 
that the stiffness was not significantly different between the two 
groups. They hypothesized that these results were due to the 
composite nature of the augmented femur: the bone governs the pre-
yield behavior and once fracture occurs, it is likely that the composite 
formed by trabecular bone and cement determines the mechanical 
response. 
To overcome the high temperature of polymerization, Beckmann et al. 
[41] tested a not-resorbable composite consisting of crosslinking 
resins and reinforcing glass ceramic particles already used for 
vertebral augmentation instead of PMMA. The author used nine pairs 
of femur as case-control; they recorded the temperature of 
polymerization and simulated a fall on the great trochanter. 
Subsequently the fractured femurs were stabilized using cannulated 
screws, a dynamic hip screw or a proximal femoral nail and they were 
then biomechanically tested again. As expected, breaking load and 
absorbed energy were significantly increased. The maximum 
temperature elevation (about 11°) was lower if compared with PMMA 
but still high if compared to the near iso-thermic polymerization 
cement based on calcium phosphate. However, the authors 
expressed concern regarding the revision surgery of the reinforced 
femur especially in the drilling: the composite was even harder to drill 
than the PMMA. Moreover, femoroplasty may directly influence the 
subsequent fracture of the augmented region: a distal shift of the 
fracture location could be assumed for in vivo condition. 
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Moreover De Bakker et al [42] in a finite elements study have shown 
how, reinforcing the femur with a Gamma nail, there was a 100% 
increase in the resistance to fracture. 
Currently, to our knowledge, there is only a device on the market, for 
the prevention of the femoral neck. Fractures. Recently it has been 
published a finite element analysis showing that this device has led to 
a decrease in the risk of femoral neck fracture (−28%) and 
trochanteric fracture (−52%) [43]. 
 
1.3 AIM 
The aim of our study is to evaluate the efficacy and safety of a new 
device: the Prevention Nail System (PNS), made by Medacta 
(Medacta International Castel San Pietro Switzerland) for the surgical 
prevention of femoral neck in elderly patients with severe 
osteoporosis. 
Secondary objectives of the study are to evaluate the bone-screw 
integration, the range of motion of the reinforced hip, the incidence of 
intra and post-operative complications such as infection and femoral 
fractures, the neck-screw angle (neutral, varus, valgus).  
In addition, the number of falls and the ambulatory patient autonomy 
will be evaluated. 
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2. MATERIALS AND METHODS 
 
2.1 DEVISE DESCRIPTION 
The PNS is a device that consists of a self-tapping cephalic screw 
[Figure 1]; it is made in a titanium alloy (Ti6Al7Nb; ISO 5832-11), with 
a Young's modulus of 14.1 10¹¹ N / m². The thread is hydroxyapatite 
coated with a diameter of 13 mm and a pitch of 3 mm; it is available in 
several sizes from 70 mm up to 110 mm. The screw head is tapered 
(taper 10-12 mm) that allows, in case of medial neck femoral fracture, 
avascular necrosis or arthritis of being coupled with a prosthetic metal 
head. 
The PNS is introduced with a minimally invasive percutaneous 
technique in the femoral neck through the lateral cortex below the 
greater trochanter after performing the treatment of contralateral 
fractured femoral neck. 
In case of throcanteric or below the trochanter fractures of the 
reinforced femur, a plate is available to fix the fracture using the PNS 
as a “lag screw” 
 
2.2 PATIENTS 
The local ethical committee approved the randomized, controlled trial 
(RCT) and all patients enrolled signed an informed consent. 
The inclusion criteria were: 
• Patients able to understand the purposes of the study and 
signing the informed consent. 
• Age  	≥ 65 years. 
• Diagnosis of medial fractures of the femoral neck. 
• Osteoporosis or osteomalacia confirmed by DXA in the not 
fractured femoral neck. 
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The exclusion criteria were: 
• Patient unable to understand the purposes of the study and / or 
sign the informed consent. 
• Previous femoral neck fractures. 
• Pathological fracture. 
• Paget's disease. 
• Primary hyperparathyroidism. 
Patients were randomized using a specific computer program. 
To evaluate the bone-screw integration a CT and X rays in AP and 
lateral view of the reinforced hip has been performed. 
In the AP radiograph it was evaluated the CCD angle of the femur 
(the angle in the frontal plane between the axis of the femoral neck 
and diaphyseal axis) [44] and the angle between the neck and the 
screw. An angle of 0 ° is an angle positioned in the middle of the 
neck, in our analysis, positive values mean a valgus positioning of the 
screw while negative values imply a varus position. 
 
2.3 SURGICAL THECNIQUE 
The PNS system can be performed under spinal or general 
anesthesia after performing the surgery of fractured side. 
The patient is supine, the hip is tractioned and the other limb is 
positioned with the thigh flexed to 90° and abducted to allow the 
passage of the C arm. 
The incision is sub-trochanteric with a longitudinal extension of 2-4 
cm. After the positioning of the guide wire and checked by the image 
intensifier in both planes: antero-posterior and axillary. 
The measurement of the length of the femoral neck is performed with 
a special device in order to choose the right size of the PNS. 
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The drill bit is inserted to open the lateral cortex and then the PNS is 
inserted with a cannulated T shaped handle. 
A "recall" screw is inserted inside the PNS to protect the internal 
thread. 
Subcutaneous tissue and skin are sutured with 2-0 absorbable wire. 
 
2.4 FOLLOW UP 
Three postoperative follow up (FU) were performed at: three months, 
twelve months and 24 months. 
During each FU X rays of the pelvis in AP and lateral view of the hip, 
a CT scans and DXA of the reinforced hip were carried out to 
evaluate bone-screw integration. 
Radiographic check also aims to describe and quantify the presence 
of complications such as heterotopic ossification, areas of osteolysis 
and loosening of the PNS. For this reason, we have identified four 
regions of interest (ROIs). [Figure 2] 
The limb function is evaluated through the range of motion (ROM) by 
measuring the degrees of flexion, extension, abduction, adduction, 
internal and external rotation, and by the presence or absence of pain 
measured with Visual Analogue Scale (VAS). All falls and their 
consequences will also be recorded. 
 
2.5 STATISTICAL ANALYSIS 
The Alpha level for statistical significance was 0.05. The descriptive 
analysis includes the arithmetic mean, standard deviation, the 
confidence interval, the median, the first and third quartile and the 
number of observations is not missing in the case of continuous 
variables. For categorical variables the absolute and relative 
frequencies were given. In addition to the primary variable will be 
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presented with a confidence interval of 95%. Changes from baseline 
status will be determined if required. 
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3. RESULTS 
 
We enrolled 80 patients with a diagnosis of femoral neck fracture: 46 
(57.5%) in the study group (A) and 34 (42.5%) in the control group 
(B). 
The mean age at surgery was 82.94 ± 5.49 years; 83 ± 5.9 years in 
group A and 82.9 ± 4.9 in group B; (p = ns). 
61 patients (76.2%) were females: 39 (63.9%) in group A and 22 
(36.1%) in group B; 19 (23.8%) were males: 7 (36.9%) in group A and 
12 (63.1%) in group B. 
The preoperative DXA was -3.28 ± 0.64. Group A -3.3 ± 0.6 and -3.3 
± 0.7 group B. [Table 1] 
All patients underwent surgery within 48 after hospital admission. 
We performed total hip arthroplasty in five patients (6.3%): (three in 
group A and two in group B); 60 patients (75%) underwent 
hemiarthroplasty (34 in group A and 26 in group B); fifteen patients 
(18.7%) underwent synthesis with cannulated screws (nine in group A 
and six in group B). [Table 2] 
In group A, in the postoperative AP X ray, the neck-screw angle was 
measured: 24 patients (52.2%) had a valgus position of the screw in 
the femoral neck ranging from 12.6° to 1° (average 5.8°); six patients 
had a neutral position of the screw and sixteen patients had a varus 
position ranging from -1° to -12.2° (average -4.8°). [Table 3] 
The average length of hospital stay was 11.9 ± 3.9 days in group A 
and 11.4 ± 4.3 days in group B (p = ns).  
All patients the first day began physical therapy; according to the 
rehabilitative treatment, full weight bearing on the reinforced limb 
(group A) or on the non-operated limb (group B) was allowed. 
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FU were carried out at three months, one year and two years. 
[Figures 3 and 4] 
In every FU, in the group A patients, an AP radiogram was performed 
to assess the presence of osteolysis around the screw, or if there was 
loosening of the device. None of the patients with surgical 
reinforcement reported areas of osteolysis or implant loosening in four 
Regions of Interest (ROIs). 
On the three months CT scan, in the transverse plane, the integration 
of the screw in the bone was evaluated.  
At the level of the lateral cortex, there was one mm gap between the 
edge of the cortical bone and the surface of the screw. This gap was 
no longer evident in the CT scan performed at twelve months FU and 
on the two years CT scan was even possible to observe an increasing   
integration. [Figure 5] 
The mean DXA T-score of the reinforced hip at three months was -3.3 
± 0.8 at one year it was -3.2 ± 0.8, and at two years was -3.5 ± 0.9. In 
all FU the DXA T-scores were not statistically significant compared 
with the preoperative. [Graphic 1] 
In every follow up the assessment of pain was performed with the 
VAS; at three months FU only one patient in group A had a VAS 
score of 8 but the pain was no more present at 12 months FU. 
At the last FU, the assessment of the walk ability was performed with 
a score developed by our group: 10 points in case of walking without 
aids; 8 in case of walking with a stick; 7 with a crutch; 6 with two 
crutches; 4 with a walker; 2 if assisted by a care giver; and 0 if not 
able to walk. [Table 4] 
All patients when admitted to hospital were not taking osteoporosis 
drugs. 
We lost one patient in group B at 1 year FU. 
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17 patients (21.2%) died before the 24 months follow up: 9 in group A 
(52.9%) and 8 in group B (47.1%). Six patients died after the two 
years follow up: five in group A and one in Group B. 
At the last follow up, 59 patients (73.7%) haven’t reported new falls; 
21 patients (26.3%) reported one or more falls. [Table 5] 
Of these patients, nine have reported one or more osteoporotic non-
femoral fractures: six in group A (66.7%) and three in group B 
(33.3%). 
In group A were recorded a wrist fracture, four vertebral collapse and 
three low energy pelvis fractures; in group B were recorded a wrist 
fracture, two humeral fractures and two vertebral collapse. [Table 6] 
Six patients: three for each group reported a second contralateral 
proximal femur fractures. In group A in all of the three patients was 
observed a below the trochanter fracture with the spiroid fracture rime 
to set off from the screw hole on the lateral cortex; all the patients 
experience the second fracture within a month after surgery. Only in 
one case the fracture was secondary to a fall; in the other 2 cases no 
falling were reported. 
Two out of three patients were admitted in the hospital for a new 
fracture synthesis with PNS related plate. The third patient was 
operated in another hospital by removing the PNS. 
All the three patients in group B reported a contralateral femoral 
fracture secondary to a new fall (two syntheses with intramedullary 
nail and an hemiarthroplasty were performed). 
One patient in group A, in which was used the plate after the 
contralateral fracture, reported a non-union of the fracture with 
progressive varization of the proximal epiphysis of the reinforced 
femur; one year later a new surgery with explant of the proximal 
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femur was performed and was implanted an hemiarthroplasty with a 
revision stem.  
On the epiphysis was performed a micro-tomographic analysis that 
showed the high rarefaction of trabecular bone of the femoral head 
and also highlights the osteointegration of the screw. [Figure 6] 
Histological analysis confirmed the severe osteoporosis but however 
an important presence of newly formed bone on the thread of the 
screw that confirms osteointegration. [Figure 7] 
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4. DISCUSSION 
 
Every year, there are over two million osteoporosis-related fractures 
in US, including hip, spine and wrist. Among these, the femoral neck 
fractures have the greatest significance in terms of morbidity and 
mortality; in addition, the direct and indirect costs of osteoporosis and 
related fractures are enormous. Due to the aging of the population by 
2025, the direct annual cost of osteoporosis will reach over 25,3 
billion dollars. Osteoporosis therefore has significant physical, 
financial and emotional consequences. [45] 
Thus, strategies must be adopted to reduce osteoporosis-related 
fractures; currently the only strategies to decrease the incidence of 
fractures are pharmacological and non-pharmacological prevention. 
The device we developed for secondary prevention of femoral neck 
fractures may be a viable solution. 
PNS resulted well tolerated: at one year FU no patients had pain in 
the reinforced hip and at 24 months FU, ROM of reinforced hip was 
wide and comparable to the not reinforced hip in group B. 
Regards the walking ability, by summing the score according to the 
degree of independence during walking and dividing the score 
obtained for the number of patients per group, it resulted in a mean 
score of 5.6 in group A and 4,0 in group B. The PNS does not 
therefore affect walking ability of the patients.   
The DXA examination carried out in the reinforced hip between the 
preoperative and the last FU performed at two years did not show a 
statistically significant difference. 
The three months CT compared to those performed at twelve and 24 
months showed good osteointegration and also no signs of sclerosis 
or osteolysis and that was also confirmed with the plan X rays of the 
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hip into the four regions of interest. The radiographic evaluation of 
neck-screw angle has not shown a correlation with the risk of fracture. 
The contralateral hip fractures in the reinforced side can be 
considered a technical error due to surgical instruments. In fact, 
during the surgery, in all three cases there was a difficult implant that 
likely resulted in the formation of micro-cracks that determined the 
fracture when the patients started to walk; another confirmation is the 
observation that the fracture line originated in all cases from the lower 
part of the screw hole on the lateral aspect of the femur. 
If we exclude the two cases of spontaneous fracture of the femur, in 
the study group, there was just a fracture of the femur against the 
three occurred in the control group. 
Limitations of this study were the lack of a system able to assess the 
strength of falls in order to understand when the energy of the fall was 
sufficient to cause a fracture in the reinforced and in the non-
reinforced femur. 
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5. CONCLUSIONS 
 
Surgical prevention could become a viable solution in the prevention 
of second femoral neck fracture in patients at risk. The right selection 
of patients is mandatory but also trials with a larger cohort should by 
designed in order to prove the efficacy of the treatment.  
Regarding the device safety, it could be increased by performing 
some technical improvement on the instruments in order to avoid the 
risk of fracture in the reinforced femur. 
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6. FIGURES AND TABLES 
 
 
 
Figure 1: A. Two different PNS length; B. PNS positioned in the femoral neck; C. 
PNS with the related plate designed in case of sub-trochanteric fractures of the 
reinforced neck. 
 	
Figure 2: Draft of the four ROIs for the evaluation of osteolysis in the AP hip X 
ray. 
C 
A 
B 
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Figure 3: 67 year old female patient; A. AP pre-operative X ray shows a left 
femoral neck fracture; B. post op x ray: on the affected hip a total hip arthroplasty 
was performed and in the right size was performed the surgical reinforcement 
with the PNS; C. DXA shows a severe osteoporosis. 
A 
C 
B 
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Figure 4: 12 months FU. A. No osteolisys are present in the reinforced neck. B. 
DXA shows a T-score slightly higher compared with the 3 months exam. C. CT 
assail slice shows good osteointegration. 
 
 	
A 
B C 
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Figure 5: CT slices of the same patient at different FU; A. Three months FU: 
there is a gap between the screw and the lateral cortex. B. 12 months FU: the 
gap although present is less evident. C: 24 months FU: the gap is no more 
present demonstrating the osteointegration capacity of the PNS. 							
 
Figure 6: Micro-tomographic analysis of the femoral head explanted during the 
revision surgery. The longitudinal cat on the major axis of the screw demonstrate 
the rarefaction of the cancellous bone. 
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Figure 7: Histological analysis of the femoral head explanted during the revision 
surgery. The pictures highlight osteointegration on the thread of the screw: A. 4x 
magnification; B. 10x magnification; C. 17x magnification. The presence of 
cartilage and osteoid shows also new bone formation. 
	 26	
 
 
Graphic 1: T score values (mean and SD) of the reinforced hip pre-operatively, 
three months, 12 months and 24 months.  
 
 
 N. Mean age Sex Pre-op. DXA  
Drugs taken at 
the H. admission  
Hospitalization 
days  
Patients 80 82,9±5,5 61 F; 19 M 
-3,28 ± 
0,64 3,9 ± 2,5 12 ± 4 
A (PNS) 46 (57.5%) 83 ±5,9 
39 F; 
7 M -3,3 ± 0,6 3,8 ± 2,5 11,9 ± 3,9 
B (Control) 34 (42.5%) 82,9±4,9 
22 F; 
12 M -3,3 ± 0,7 3,9 ± 2,6 11,4 ± 4,3 
 
Table 1: Patients enrolled in the study. 
 
 
 
Surgery Total Hip Arthroplasty  Hemiarthroplasty 
Cannulated 
screw synthesis Total 
Group A 3 (6.5%) 34 (73.9%) 9 (19.6%) 46 
Group B 2 (5.9%) 26 (76.4%) 6 (17.7%) 34 
Amount 5 (6.3%) 60 (75%) 15 (18.7%) 80 
 
Table 2: Surgery at the fractured hip. 
 
 
 
-3,28 -3,27 -3,16 
-3,45 
-4,50 
-4,00 
-3,50 
-3,00 
-2,50 
-2,00 
pre 3mesi 12 mesi 24 mesi 
media 
	 27	
 
Screw placement Valgus Neutral Varus 
Patients 24 6 16 
Neck-screw angle 
(Mean SD) 5.8°± 3.5°  - -4.8°± 2.8°  
 
Table 3: Evaluation of neck-screw angle in patients underwent surgical 
reinforcement. 	
 
Walking ability Score Group A Group B 
No aids 10 14 8 
One cane 8 7 4 
One crutch 7 2 6 
Two crutches 6 3 1 
Walker 4 7 2 
Care giver 2 5 1 
Not able to walk 0 8 12 
 
Table 4: Walking ability of patients underwent surgical reinforcement at two years 
F.U. 
 
 
 Patients referred one or more fall Total falls Total fractures 
Non-femoral 
fractures 
Group A  13 34 13 10 
Group B  8 19 9 6 
Total 21 53 22 16 
 
Table 5: Patients that reported one or more falls after surgical reinforcement.  
 
 
 
Fracture type Vertebral Wrist Shoulder Pelvis Femoral 
Group A 6 1 - 3 3* 
Group B 3 1 2 - 3 
Total 9 2 2 3 6 
 
Table 6: fractures divided by anatomical region.  
* Two patients in group A reported a femoral fracture without a fall. 
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